Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors thank the patients who participated in this study and their families, and the study investigators and coordinators at MD Anderson for sample and data collection.

Authors contributions

PJ, AG and ACL conceived the study, PJ designed research and worked on study protocol, AG, AF, ACL, and PJ worked on data collection, sample collection, clinical and genomic data organization and coordinating all aspects of the manuscript. All other authors participated in patient accrual, management, and data collection. All authors critically reviewed and edited the manuscript for important intellectual content. The principal investigator, PJ, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Disclosure statement

SA received research funding from Seattle Genetics, Merck, Xencor, Chimagen and Tessa Therapeutics, has membership on scientific advisory committee for Tessa Therapeutics and Chimagen, serves on Data Safety Monitoring Board for Myeloid Therapeutics and is a consultant for ADC therapeutics and KITE/Gilead. SPI receives research support from CRISPR Therapeutics, Myeloid, Merck, Seagen, Ono, Rhizen, Acrotech, Legend, Innate Pharma, Astra Zeneca, Dren Bio, Yingli, and Secura Bio; participates in scientific advisory boards for Seagen, Yingli, and Secura Bio; and participates as speaker for American Society of Hematology, American Society of Cellular Therapy and Transplantation, Biocure and Targeted Oncology’s speaker bureaus. LJN has received advisory board honorarium and research support from Janssen. JW has received research funding from Kite/Gilead, Novartis, BMS, Genentech, AstraZeneca, Janssen, Morphosys/Incyte, Precision Biosciences, and ADC Therapeutics and has received consulting funding from Kite/Gilead, Novartis, BMS, Janssen, AstraZeneca, Genentech, Morphosys/Incyte, ADC Therapeutics, Iksuda, Umoja, MonteRosa, and Merck. CF has received consultancy funding from Abbvie, Bayer, BeiGene, Celgene, Denovo Biopharma, Epizyme, Genentech/Roche, Gilead, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, Spectrum and research funding from Abbvie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, CPRIT, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation. SSN received research support from Kite/Gilead, BMS, Allogene, Precision Biosciences and Adicet Bio; served as Advisory Board Member/Consultant for Kite/Gilead, Merck, Sellas Life Sciences, Athenex, Allogene, Incyte, Adicet Bio, BMS, Bluebird Bio, Fosun Kite, Sana Biotechnology, Caribou, Astellas Pharma, MorphoSys, Janssen, Chimagen, ImmunoACT, Orna Therapeutics, Takeda and Synthekine; has stock options from Longbow Immunotherapy. MW has received research funding from Pharmacyclics, Janssen, AstraZeneca, Celgene, Loxo Oncology, Kite Pharma, Juno, BioInvent, VelosBio, Acerta Pharma, Oncternal, Verastem, Molecular Templates, Lilly, Innocare; honoraria from Janssen, Acerta Pharma, OMI, Physicians Education Resources, Dava Oncology, CAHON, Hebei Cancer Prevention Federation, Clinical Care Options, Mumbai Hematology Group, Anticancer Association, Newbridge Pharmaceuticals and consultancy funding from InnoCare, Loxo Oncology, Juno, Oncternal, CStone, AstraZeneca, Janssen, VelosBio, Pharmacyclics, Genentech, Bayer Healthcare. PJ has received research funding from Astra Zeneca, Kite, Beigene; honoraria from Aptitude Health, Pharmacy times, Dava Oncology, Adaptive Biotech, Eli Lilly, Beigene and advisory board funding from Eli Lilly, Kite, LOXO Oncology, Incyte and Janssen-PCYC.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.